LT2753313T - Farmacinės kompozicijos, apimančios aromatazės inhibitorių - Google Patents

Farmacinės kompozicijos, apimančios aromatazės inhibitorių

Info

Publication number: LT2753313T
Authority: LT; Lithuania
Prior art keywords: pharmaceutical compositions; aromatase inhibitor; aromatase; inhibitor; pharmaceutical
Prior art date: 2011-09-08

Application number

LTEP12758966.1T

Other languages

English (en)

Inventor

Ann Taylor

Lloyd B. Klickstein

Jeewan Thakur

Original Assignee

Mereo Biopharma 2 Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-09-08

Filing date

2012-09-06

Publication date

2017-02-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46846026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2753313(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-09-06 Application filed by Mereo Biopharma 2 Limited filed Critical Mereo Biopharma 2 Limited

2017-02-10 Publication of LT2753313T publication Critical patent/LT2753313T/lt

Links

229940122815 Aromatase inhibitor Drugs 0.000 title 1
239000003886 aromatase inhibitor Substances 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Reproductive Health (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Obesity (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Inorganic Chemistry (AREA)
Gynecology & Obstetrics (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Pregnancy & Childbirth (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

LTEP12758966.1T 2011-09-08 2012-09-06 Farmacinės kompozicijos, apimančios aromatazės inhibitorių LT2753313T (lt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161532459P	2011-09-08	2011-09-08
US201261638588P	2012-04-26	2012-04-26
PCT/US2012/053846 WO2013036563A1 (en)	2011-09-08	2012-09-06	Pharmaceutical compositions comprising an aromatase inhibitor

Publications (1)

Publication Number	Publication Date
LT2753313T true LT2753313T (lt)	2017-02-10

Family

ID=46846026

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP12758965.3T LT2753312T (lt)	2011-09-08	2012-09-06	Aromatazės inhibitoriaus panaudojimas hipogonadizmo ir susijusių ligų gydymui
LTEP12758966.1T LT2753313T (lt)	2011-09-08	2012-09-06	Farmacinės kompozicijos, apimančios aromatazės inhibitorių

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LTEP12758965.3T LT2753312T (lt)	2011-09-08	2012-09-06	Aromatazės inhibitoriaus panaudojimas hipogonadizmo ir susijusių ligų gydymui

Country Status (31)

Country	Link
US (4)	US9295668B2 (lt)
EP (2)	EP2753312B1 (lt)
JP (2)	JP6280501B2 (lt)
KR (3)	KR20180030254A (lt)
CN (2)	CN103796644B (lt)
AR (1)	AR087790A1 (lt)
AU (2)	AU2012304693B2 (lt)
BR (2)	BR112014005434B1 (lt)
CA (2)	CA2846884C (lt)
CL (1)	CL2014000552A1 (lt)
CY (2)	CY1118461T1 (lt)
DK (2)	DK2753312T3 (lt)
ES (2)	ES2613666T3 (lt)
HR (2)	HRP20170002T1 (lt)
HU (2)	HUE031478T2 (lt)
IL (1)	IL231234A (lt)
IN (1)	IN2014DN01619A (lt)
LT (2)	LT2753312T (lt)
MX (2)	MX343902B (lt)
PE (1)	PE20141584A1 (lt)
PH (1)	PH12014500435A1 (lt)
PL (2)	PL2753312T3 (lt)
PT (2)	PT2753312T (lt)
RU (2)	RU2617510C2 (lt)
SG (2)	SG2014012132A (lt)
SI (2)	SI2753312T1 (lt)
TN (1)	TN2014000059A1 (lt)
TW (1)	TW201316987A (lt)
UY (1)	UY34315A (lt)
WO (2)	WO2013036562A1 (lt)
ZA (1)	ZA201401040B (lt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6280501B2 (ja) *	2011-09-08	2018-02-14	メレオバイオファーマ２リミテッド	性腺機能低下症および関連疾患の処置ためのアロマターゼ阻害剤の使用
WO2015148549A1 (en) *	2014-03-26	2015-10-01	The Regents Of The University Of California	Ultrasensitive androgen receptor bioassay
SI3166596T1 (sl) *	2014-07-07	2018-10-30	Novartis Ag	Farmacevtske odmerne oblike
GB201614179D0 (en) *	2016-08-19	2016-10-05	Mereo Biopharma 2 Ltd	Dosage regimen for the treatment of endometriosis
CN110520110A (zh) *	2017-03-08	2019-11-29	阿瑞雅德制药公司	包含5-氯-n4-[2-(二甲基磷酰基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺的药物制剂
IL322969A (en)	2017-10-12	2025-10-01	Novo Nordisk As	Semaglutide in medical therapy
USD894149S1 (en) *	2018-08-16	2020-08-25	Alibaba Group Holding Limited	Information terminal for payment
USD894148S1 (en) *	2018-08-16	2020-08-25	Alibaba Group Holding Limited	Information terminal for payment
JP7121999B2 (ja) *	2019-09-26	2022-08-19	学校法人九州文化学園	男性性腺機能低下症治療剤
US12552754B1 (en)	2025-06-11	2026-02-17	ReproNovo SA	Leflutrozole compositions of matter and processes for preparation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4749713A (en)	1986-03-07	1988-06-07	Ciba-Geigy Corporation	Alpha-heterocycle substituted tolunitriles
TW210334B (lt)	1990-12-12	1993-08-01	Ciba Geigy Ag
DE4435368A1 (de) *	1994-09-22	1996-03-28	Schering Ag	Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
US5972921A (en) *	1997-12-12	1999-10-26	Hormos Medical Oy Ltd.	Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
AU2001271162A1 (en) *	2000-07-05	2002-01-14	Astrazeneca Ab	Pharmaceutical combination of an anti-androgen and letrozole for providing an anit-androgenic effect and aromatase inhibition
CZ299735B6 (cs) *	2001-04-17	2008-11-05	Ares Trading S. A.	Farmaceutický prostredek
US7101573B2 (en)	2001-09-28	2006-09-05	Mcneil-Pcc, Inc.	Simethicone solid oral dosage form
EP1492515A1 (en) *	2002-04-03	2005-01-05	Jencap Research Ltd.	Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male
EP1937251A2 (en)	2005-04-25	2008-07-02	Pfizer Products Inc.	Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
JPWO2009066712A1 (ja)	2007-11-21	2011-04-07	クラシエ製薬株式会社	アロマターゼ阻害剤
JP6280501B2 (ja) *	2011-09-08	2018-02-14	メレオバイオファーマ２リミテッド	性腺機能低下症および関連疾患の処置ためのアロマターゼ阻害剤の使用

2012
- 2012-09-06 JP JP2014529832A patent/JP6280501B2/ja active Active
- 2012-09-06 HU HUE12758965A patent/HUE031478T2/hu unknown
- 2012-09-06 MX MX2014002773A patent/MX343902B/es active IP Right Grant
- 2012-09-06 ES ES12758965.3T patent/ES2613666T3/es active Active
- 2012-09-06 SI SI201230850T patent/SI2753312T1/sl unknown
- 2012-09-06 US US14/342,810 patent/US9295668B2/en active Active
- 2012-09-06 LT LTEP12758965.3T patent/LT2753312T/lt unknown
- 2012-09-06 AR ARP120103283A patent/AR087790A1/es unknown
- 2012-09-06 CA CA2846884A patent/CA2846884C/en active Active
- 2012-09-06 DK DK12758965.3T patent/DK2753312T3/da active
- 2012-09-06 LT LTEP12758966.1T patent/LT2753313T/lt unknown
- 2012-09-06 HR HRP20170002TT patent/HRP20170002T1/hr unknown
- 2012-09-06 HU HUE12758966A patent/HUE031435T2/en unknown
- 2012-09-06 DK DK12758966.1T patent/DK2753313T3/en active
- 2012-09-06 WO PCT/US2012/053844 patent/WO2013036562A1/en not_active Ceased
- 2012-09-06 AU AU2012304693A patent/AU2012304693B2/en active Active
- 2012-09-06 WO PCT/US2012/053846 patent/WO2013036563A1/en not_active Ceased
- 2012-09-06 ES ES12758966.1T patent/ES2613667T3/es active Active
- 2012-09-06 SG SG2014012132A patent/SG2014012132A/en unknown
- 2012-09-06 KR KR1020187007058A patent/KR20180030254A/ko not_active Ceased
- 2012-09-06 PL PL12758965T patent/PL2753312T3/pl unknown
- 2012-09-06 KR KR1020147006170A patent/KR20140071358A/ko not_active Ceased
- 2012-09-06 EP EP12758965.3A patent/EP2753312B1/en active Active
- 2012-09-06 PT PT127589653T patent/PT2753312T/pt unknown
- 2012-09-06 BR BR112014005434-7A patent/BR112014005434B1/pt active IP Right Grant
- 2012-09-06 SI SI201230848A patent/SI2753313T1/sl unknown
- 2012-09-06 PT PT127589661T patent/PT2753313T/pt unknown
- 2012-09-06 RU RU2014113575A patent/RU2617510C2/ru active
- 2012-09-06 PE PE2014000325A patent/PE20141584A1/es not_active Application Discontinuation
- 2012-09-06 SG SG10201607503WA patent/SG10201607503WA/en unknown
- 2012-09-06 BR BR112014004879A patent/BR112014004879B1/pt active IP Right Grant
- 2012-09-06 PH PH1/2014/500435A patent/PH12014500435A1/en unknown
- 2012-09-06 PL PL12758966T patent/PL2753313T3/pl unknown
- 2012-09-06 CA CA2845929A patent/CA2845929C/en active Active
- 2012-09-06 EP EP12758966.1A patent/EP2753313B1/en active Active
- 2012-09-06 IN IN1619DEN2014 patent/IN2014DN01619A/en unknown
- 2012-09-06 AU AU2012304694A patent/AU2012304694B2/en active Active
- 2012-09-06 HR HRP20170003TT patent/HRP20170003T1/hr unknown
- 2012-09-06 US US14/342,813 patent/US9370505B2/en active Active
- 2012-09-06 MX MX2014002780A patent/MX360315B/es active IP Right Grant
- 2012-09-06 KR KR1020147006171A patent/KR101872561B1/ko active Active
- 2012-09-06 JP JP2014529833A patent/JP6051467B2/ja active Active
- 2012-09-06 CN CN201280043378.9A patent/CN103796644B/zh active Active
- 2012-09-06 RU RU2014113334A patent/RU2628808C2/ru active
- 2012-09-06 CN CN201280043614.7A patent/CN103781476B/zh active Active
- 2012-09-07 TW TW101132840A patent/TW201316987A/zh unknown
- 2012-09-10 UY UY0001034315A patent/UY34315A/es not_active Application Discontinuation
2014
- 2014-02-10 TN TNP2014000059A patent/TN2014000059A1/en unknown
- 2014-02-11 ZA ZA2014/01040A patent/ZA201401040B/en unknown
- 2014-02-27 IL IL231234A patent/IL231234A/en active IP Right Grant
- 2014-03-07 CL CL2014000552A patent/CL2014000552A1/es unknown
2016
- 2016-02-22 US US15/050,394 patent/US9750724B2/en active Active
- 2016-05-27 US US15/167,867 patent/US10064844B2/en active Active
2017
- 2017-01-18 CY CY20171100074T patent/CY1118461T1/el unknown
- 2017-01-24 CY CY20171100100T patent/CY1118499T1/el unknown

Also Published As

Publication number	Publication date
JP2014526465A (ja)	2014-10-06
US20140213622A1 (en)	2014-07-31
PL2753312T3 (pl)	2017-06-30
HUE031478T2 (hu)	2017-07-28
MX343902B (es)	2016-11-28
WO2013036562A1 (en)	2013-03-14
SG2014012132A (en)	2014-06-27
KR101872561B1 (ko)	2018-06-28
JP6051467B2 (ja)	2016-12-27
JP6280501B2 (ja)	2018-02-14
US9370505B2 (en)	2016-06-21
CA2846884A1 (en)	2013-03-14
BR112014005434A2 (pt)	2017-04-04
CL2014000552A1 (es)	2014-09-12
TN2014000059A1 (en)	2015-07-01
HRP20170003T1 (hr)	2017-03-10
CN103796644B (zh)	2017-05-03
CA2846884C (en)	2019-04-09
US9750724B2 (en)	2017-09-05
DK2753313T3 (en)	2017-02-13
BR112014005434B1 (pt)	2021-01-05
MX360315B (es)	2018-10-29
MX2014002773A (es)	2014-06-05
US20140309267A1 (en)	2014-10-16
EP2753313B1 (en)	2016-12-14
CY1118499T1 (el)	2017-07-12
EP2753313A1 (en)	2014-07-16
LT2753312T (lt)	2017-01-25
US20160346257A1 (en)	2016-12-01
WO2013036563A1 (en)	2013-03-14
AU2012304694B2 (en)	2016-04-07
DK2753312T3 (da)	2017-02-13
US10064844B2 (en)	2018-09-04
CN103781476B (zh)	2016-12-07
AU2012304693B2 (en)	2016-03-31
AR087790A1 (es)	2014-04-16
CN103781476A (zh)	2014-05-07
SG10201607503WA (en)	2016-10-28
BR112014004879B1 (pt)	2020-01-28
KR20140058619A (ko)	2014-05-14
EP2753312B1 (en)	2016-12-14
CN103796644A (zh)	2014-05-14
PT2753312T (pt)	2017-02-03
RU2014113575A (ru)	2015-10-20
ES2613667T3 (es)	2017-05-25
JP2014528932A (ja)	2014-10-30
MX2014002780A (es)	2014-06-05
HRP20170002T1 (hr)	2017-02-24
RU2628808C2 (ru)	2017-08-22
KR20140071358A (ko)	2014-06-11
US9295668B2 (en)	2016-03-29
CA2845929C (en)	2018-06-19
IN2014DN01619A (lt)	2015-05-15
PL2753313T3 (pl)	2017-07-31
EP2753312A1 (en)	2014-07-16
RU2617510C2 (ru)	2017-04-25
RU2014113334A (ru)	2015-10-20
AU2012304694A1 (en)	2014-03-20
UY34315A (es)	2013-04-30
SI2753312T1 (sl)	2017-10-30
AU2012304693A1 (en)	2014-03-13
BR112014004879A2 (pt)	2017-03-14
TW201316987A (zh)	2013-05-01
US20160243084A1 (en)	2016-08-25
ZA201401040B (en)	2015-12-23
IL231234A (en)	2016-12-29
PT2753313T (pt)	2017-02-02
CA2845929A1 (en)	2013-03-14
NZ621476A (en)	2016-02-26
IL231234A0 (en)	2014-04-30
HUE031435T2 (en)	2017-07-28
ES2613666T3 (es)	2017-05-25
KR20180030254A (ko)	2018-03-21
PH12014500435A1 (en)	2019-03-22
CY1118461T1 (el)	2017-07-12
SI2753313T1 (sl)	2017-04-26
PE20141584A1 (es)	2014-11-13

Publication	Publication Date	Title
TWI560172B (en)	2016-12-01	Neprilysin inhibitors
GB201113662D0 (en)	2011-09-21	Pharmaceutical compositions
AP3656A (en)	2016-04-04	Pharmaceutical compositions
IL231961A0 (en)	2014-05-28	Bleeding agents
IL232147A0 (en)	2014-05-28	Bleeding agents
PL2791160T3 (pl)	2022-06-20	Kompozycje zmodyfikowanego mrna
AP2013007227A0 (en)	2013-11-30	Pharmaceutical composition
ZA201308208B (en)	2014-06-25	Pharmaceutical compositions
ZA201305826B (en)	2014-04-30	Substituted amminobutyric derivatives as neprilysin inhibitors
PL3513803T3 (pl)	2021-11-22	Kompozycje hemostatyczne
ZA201301766B (en)	2016-11-30	Pharmaceutical compositions
SI2753313T1 (sl)	2017-04-26	Farmacevtski sestavki, ki obsegajo inhibitor aromataze
GB201118232D0 (en)	2011-12-07	Pharmaceutical composition
ZA201308157B (en)	2015-01-28	Pharmaceutical composition
IL226554A (en)	2017-12-31	Medicinal preparations containing alisporiovir
GB201118181D0 (en)	2011-12-07	Pharmaceutical compositions
PL2363354T3 (pl)	2013-05-31	Dozownik substancji czynnej
ZA201309537B (en)	2015-04-29	Pharmaceutical composition comprising fexofedine
PT3513803T (pt)	2021-08-10	Composições hemostáticas
GB201120474D0 (en)	2012-01-11	Inhibitors